Clinical trial · Interventional
Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
Comprehensive Local Consolidative Therapy Versus Continued Sintilimab Plus Lenvatinib Alone After Induction Sintilimab Plus Lenvatinib in Patients With Oligo-Extrahepatic Metastatic Hepatocellular Carcinoma: A Multicenter Prospective Randomized Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluates whether comprehensive local consolidative therapy added to continued sintilimab plus lenvatinib improves survival compared with continued sintilimab plus lenvatinib alone in patients with oligo-extrahepatic metastatic hepatocellular carcinoma. All enrolled participants receive induction treatment with sintilimab plus lenvatinib for 4 cycles. Participants who achieve disease control and are confirmed by central multidisciplinary review to be feasible for complete consolidation are randomized in a 1:1 ratio to receive either comprehensive local consolidative therapy followed by continued systemic therapy or continued systemic therapy alone. The primary outcome is overall survival.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.85 |
| Metastases | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Comprehensive Local Consolidative Therapy | Procedure | — | UNRESOLVED |
| Lenvatinib | Drug | Lenvatinib | ALIAS |
| Sintilimab | Drug | Sintilimab | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Induction Sintilimab Plus Lenvatinib Followed by Comprehensive Local Consolidative Therapy and Conti
- description
- All enrolled participants receive induction sintilimab plus lenvatinib. Participants who achieve disease control and are confirmed by central multidisciplinary review to be feasible for full-lesion consolidation are randomized to receive comprehensive local consolidative therapy to all residual active lesions within 4 to 8 weeks after randomization, followed by continued sintilimab plus lenvatinib.
- interventionNames
- Drug: Sintilimab
- Drug: Lenvatinib
- Procedure: Comprehensive Local Consolidative Therapy
- type
- ACTIVE_COMPARATOR
- label
- Induction Sintilimab Plus Lenvatinib Followed by Continued Systemic Therapy Alone
- description
- All enrolled participants receive induction sintilimab plus lenvatinib. Participants who achieve disease control and are confirmed by central multidisciplinary review to be feasible for full-lesion consolidation are randomized to continue sintilimab plus lenvatinib alone without protocol-planned comprehensive local consolidative therapy before RECIST-defined progression.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 to 75 years * Hepatocellular carcinoma confirmed by imaging and/or histology according to institutional diagnostic standards * Advanced or unresectable disease with extrahepatic metastases meeting protocol-defined oligo-extrahepatic metastatic disease criteria: 1 to 5 extrahepatic metastatic lesions and no more than 2 involved extrahepatic organs * At least 1 measurable lesion according to RECIST version 1.1 * No prior systemic therapy for advanced or metastatic hepatocellular carcinoma * ECOG performance status 0 to 1 * Child-Pugh class A or stable Child-Pugh B7 * Adequate hematologic, hepatic, renal, and coagulation function according to protocol * Baseline center multidisciplinary team assessment indicating potential feasibility for complete consolidative intent if disease control is achieved after induction * Written informed consent and willingness to comply with treatment, follow-up, and protocol-required assessments Exclusion Criteria: * More than 5 extrahepatic metastatic lesions or more than 2 involved extrahepatic organs * Diffuse peritoneal seeding, leptomeningeal disease, or uncontrolled brain metastases * Main portal vein trunk invasion, extensive inferior vena cava or right atrial tumor thrombus, or disease considered unlikely to become fully consolidable after induction * Diffuse intrahepatic disease or liver tumor burden considered unlikely to be controllable with protocol-specified local treatment * Prior PD-1, PD-L1, CTLA-4, anti-VEGF monoclonal antibody, tyrosine kinase inhibitor, or other systemic antitumor therapy for advanced HCC * Active autoimmune disease requiring systemic immunosuppression * Active severe infection, including uncontrolled bacterial or fungal infection, active tuberculosis, or uncontrolled hepatitis B without appropriate antiviral therapy * Gastrointestinal bleeding within the previous 6 months, or untreated or uncontrolled high-risk gastroesophageal varices * Uncontrolled hypertension, recent major thrombotic event, myocardial infarction, unstable angina, or stroke * Active interstitial lung disease or noninfectious pneumonitis requiring systemic treatment * Severe proteinuria or renal dysfunction considered unsuitable for lenvatinib treatment * Pregnancy or breastfeeding * Any condition that, in the investigator's judgment, would make participation unsafe or compromise protocol compliance
References
Publications (0)
Data not yet available